Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ribavirin
- Development stage
- Approved
- Lead developer
- ICN Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Inhalation, Intravenous
01
Overview
Ribavirin is a synthetic guanosine nucleoside analog and broad-spectrum antiviral medication. It is primarily used in combination with other drugs to treat chronic hepatitis C virus (HCV) infection and certain viral hemorrhagic fevers such as Lassa fever, Crimean–Congo hemorrhagic fever, and Hantavirus infections. Ribavirin also has activity against respiratory syncytial virus (RSV). Its mechanism of action involves inhibition of viral RNA synthesis and mRNA capping by interfering with the synthesis of viral mRNA after being metabolized into active nucleoside analogs. Ribavirin is not effective as monotherapy for HCV; it must be combined with interferon-based therapies or direct-acting antivirals. The drug can cause significant side effects including hemolytic anemia and teratogenicity; effective contraception is required during treatment and for months afterward[1][2][3][5].
- Brand names
- CopegusModeribaRibaPakRibaTabIbavyrRebetolVirazole
- Other names
- ICN-1229ICN1229ICN 1229
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ribavirin.